CTOs on the Move


 
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.geron.com
  • 149 Commonwealth Drive
    Menlo Park, CA USA 94025
  • Phone: 650.473.7700

Executives

Name Title Contact Details
Brian Blood
Vice President Information Technology Profile
Andrew Grethlein
Executive Vice President and Chief Operating Officer Profile

Similar Companies

Etowah Landing Care

Etowah Landing is a post-acute care facility that provides a custom-tailored, medically driven rehabilitation program for fast recovery.

Transtech Medical Solutions

Transtech Medical Solutions, LLC is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DaRTChart Systems

DaRTChart Systems is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Milwaukee, WI. To find more information about DaRTChart Systems, please visit www.dartchart.com

LifeStream Behavioral Center

LifeStream Behavioral Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. LifeStream Behavioral Center is based in Leesburg, FL. You can find more information on LifeStream Behavioral Center at www.lsbc.net

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.